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doi:10.1016/j.ejmp.2012.04.006Abstract Purpose: To determine the usefulness of abdominal compression in lung stereo-
tactic body radiation therapy (SBRT) depending on lobe tumor location.
Materials and methods: Twenty-seven non-small cell lung cancer patients were immobilized in
the Stereotactic Body Frame (Elekta). Eighteen tumors were located in an upper lobe, one in
the middle lobe and nine in a lower lobe (one patient had two lesions). All patients underwent
two four-dimensional computed tomography (4DCT) scans, with and without abdominal
compression. Three-dimensional tumor motion amplitude was determined using manual
landmark annotation. We also determined the internal target volume (ITV) and the influence
of abdominal compression on lung dose-volume histograms.
Results: The mean reduction of tumor motion amplitude was 3.5 mm (p Z 0.009) for lower
lobe tumors and 0.8 mm (p Z 0.026) for upper/middle lobe locations. Compression increased
tumor motion in 5 cases. Mean ITV reduction was 3.6 cm3 (p Z 0.039) for lower lobe and
0.2 cm3 (pZ 0.048) for upper/middle lobe lesions. Dosimetric gain of the compression for lung
sparing was not clinically relevant.utte Contre le Cancer Le´on Be´rard, Service de Radiothe´rapie-Physique, 28 rue Laennec, 69008 Lyon,
þ33 4 78 78 59 98.
sa-lyon.fr (G. Bouilhol).
2 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.
334 G. Bouilhol et al.Conclusions: The most significant impact of abdominal compression was obtained in patients
with lower lobe tumors. However, minor or negative effects of compression were reported for
other patients and lung sparing was not substantially improved. At our institute, patients with
upper ormiddle lobe lesions are now systematically treatedwithout compression and the useful-
ness of compression for lower lobe tumors is evaluated on an individual basis.
ª 2012 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.Introduction
Conventional radiation therapy for medically inoperable
early stage non-small cell lung cancers (NSCLC) is associ-
ated with poor local control and survival rate [1]. Stereo-
tactic body radiation therapy (SBRT) is an effective
alternative for malignancies like these as it substantially
improves treatment outcomes [2e6]. SBRT consists in the
delivery of ablative radiation doses in hypofractionated
schedules with 5 fractions or less in order to improve tumor
local control up to 90% with biologically equivalent doses
that can exceed 150 Gy [7]. To achieve acceptable normal
tissue exposure, small T1-T2N0M0 peripheral tumors with
a diameter smaller than 5 cm and a distance to the prox-
imal bronchial tree greater than 2 cm are typically treated
with SBRT [8,9]. In practice, the delivery of such high doses
per fraction requires very high setup accuracy and robust
motion management, with highly conformal beam
arrangements and small safety margins.
Immobilization of the patient can be enforced with
commercially available devices [10], e.g. stereotactic
frames [11,12] or vacuum systems [13]. Accurate knowl-
edge of the position and shape of the gross tumor volume
(GTV) during the breathing cycle is essential and assess-
ment by four-dimensional computed tomography (4DCT) is
recommended [14]. A common irradiation strategy consists
in irradiating the internal target volume (ITV), corre-
sponding to the volume covered by the moving GTV. The
maximum intensity projection (MIP) images derived from
the 4DCT dataset can be used to delineate the ITV [15].
An abdominal compression device can be added to the
stereotactic frame to reduce tumor motion and associated
margins [16,17]. However, it may cause discomfort with
possible anxiety for some patients, being a potential source
of increase of tumor motion variability according to Bis-
sonnette et al. [18]. Moreover, it is unusable for obese
patients, and at our institute we estimate that this tech-
nique increases treatment preparation time by about
45 min (see Patient immobilization and CT scan acquisitions
sections for more details) and daily in-room time by about
10 min in comparison to conventional treatments.
The efficiency of abdominal compression for reducing
lung tumor motion has been assessed in several studies
[19e22]. These studies did not give three-dimensional
results [19] according to lobe tumor location [19e21] or
reported results substantially different from ours [22]. The
dosimetric impact of abdominal compression on irradiated
lung tissue has been investigated by Kontrisova et al. [23]
but results were not given according to lobe tumor location.
The present retrospective study aimed at evaluating the
relevance of abdominal compression in 27 SBRT patients,
depending on tumor location within the lung. We firstquantified the influence of abdominal compression on
geometrical parameters. The efficiency of abdominal
compression for reducing three-dimensional tumor motion and
the ITV was evaluated on 4DCT images acquired with and
without compression. The second part of the study aimed at
quantifying the influence of abdominal compression on dosi-
metric parameters in order to estimate the possible improve-
ment in lung toxicity. The measurements and calculations
presented in this paper systematically took into accountmotion
artifacts in 4DCT images (see description ofGeometrical study).
Materials and methods
Patient and tumor characteristics
Twenty-seven peripheral NSCLC patients who underwent
lung SBRT were included in this study, corresponding to
twenty-eight tumors (one patient had two lung lesions).
Eighteen tumors were located in the upper lobe, one in the
middle lobe and nine in the lower lobe. The patients were
divided in two groups: lower lobe and upper/middle lobe.
This distinction was made considering that diaphragmatic
motion is higher in its posterior region, where the lower lobe
is located, in contrast to the upper lobe and themiddle lobe.
Patient immobilization
All patients were installed in the Stereotactic Body Frame
(SBF, Elekta AB, Stockholm, Sweden) associated to the
abdominal compression plate. The compression level was
then adjusted under fluoroscopy using the in-room cone-
beam CT system to reduce residual diaphragmatic motion
amplitude below 1 cm in the cranio-caudal direction [24].
CT scan acquisitions
Patients underwent two helical 4DCT scans using the Bril-
lianceBig Bore (Philips) CTsimulation system.Thefirst scan
was performedwithout compression and the second onewith
pre-determined compression. CTscans were performedwith
a 0.5 s rotation period and a 0.1 pitch. The beam collimation
width was 24 mm (16  1.5 mm) and breathing synchroniza-
tion was achieved with the Pneumo Chest Bellows (Lafay-
ette Instrument). Ten phases, the MIP images [25] and the
untagged CT sets were reconstructed from the two 4DCT
scans. The untagged images resulted from the 3D tomo-
graphic reconstruction using all data, i.e. without any
respiration-correlated data binning. In this way, blurred
images are obtained, reflecting the average density of the
structures during the breathing cycle. The voxel size was
1.17  1.17  2 mm3 (where 2 mm is the slice thickness).
Figure 2 Illustration of the landmark registration method
with an artifact in the tumor region in an end-inhale phase:
selection of a voxel representing the highest tumor motion
amplitude.
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The geometrical study was performed with home-made
open-source software dedicated to 4D visualization and
image processing [26,27]. In previous studies [20,21], tumor
motion was assessed by measuring the displacement of its
centre of mass. However the position of the centre of mass
depends on the presence of motion artifacts in the tumor
area. The present method consisted in measuring three-
dimensional tumor motion amplitude on the 4DCT data-
sets with manual landmark annotation (tumor deformation
was overlooked). The chosen landmarks were particulari-
ties of the tumor surface identifiable in a reproducible way
from one extreme phase of the respiratory cycle to the
other and from one acquisition to the other (with/without
compression). The method consisted in displaying simulta-
neously the four images corresponding to end-exhale and
end-inhale phases, with and without compression. For each
acquisition, the tumor extreme phases were preliminarily
determined by visualizing the complete 4DCT dataset.
Then, we identified the corresponding slices of the tumor
on the four images. The same recognizable voxel was
selected by progressive zooming (Fig. 1). Method and
images used for image annotation were similar to those
used by Vandemeulebroucke et al. [28] who evaluated the
inter-observer variability with the mean distance between
annotations at 0.5 mm (SD 0.9 mm). To account for motion
artifacts in the tumor region and ensure the consistency of
the measurement method, landmarks were chosen in order
to reflect the largest tumor motion amplitude at the
extreme phases, representing the tumor motion amplitude
closest to the maximum tumor excursion. Figure 2 shows an
example of landmark placement in case of an artifact in an
end-inhale image. In this case, the tumor is supposed to be
at its lowest position.
The modification of the tumor motion amplitude
provides no volumetric information because this dependsFigure 1 Landmark registration between the four 4DCT phases
Selection of the corresponding slices on the four images in the tumon the tumor size. We studied the influence of abdominal
compression on the ITV. Problems induced by motion arti-
facts can lead to errors in the estimation of the ITV if
measured from the MIP volume. This way, differences in ITV
size between images acquired with and without compres-
sion can be missed or falsely detected. For this reason,
a theoretical study based on the previous landmark regis-
tration was performed. The goal was to form a global idea
of how the ITV is influenced by the use of compression. We
considered each tumor as a sphere moving along a straight
line from one extreme phase to the other. The ITV is then
given by the following formula:(end-exhale and end-inhale, with and without compression).
or region and selection of the same recognizable voxel.
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p r3 þp r2A3D; ð1Þ
where r is the tumor radius and A3D the overall motion
amplitude between extreme phases.
Paired t-tests between geometrical results obtained
with and without abdominal compression were performed
in order to quantify the statistical significance of the gain
obtained with abdominal compression.
Dosimetric study
As observed by Yamamoto et al. [29], most 4DCT images
from the 27 patients contained artifacts. Dosimetric
calculation using images with artifacts cannot provide
relevant results, particularly in case of artifacts in the
tumor region or in critical structures as mentioned in the
report of AAPM Task Group 101 [10]. Indeed, motion arti-
facts can result in errors in ITV delineation and in lung
delineation. In addition, motion artifacts impact differently
images acquired with and without abdominal compression
(see Discussion section for more details) so that it becomes
difficult to attribute dosimetric gains to the use of
compression or to motion artifacts. Therefore, only
patients without artifacts seriously impacting the ITV or the
lung volume were selected for the study. Moreover, among
these patients we selected those with the highest
geometrical efficiency based on the geometrical study,
resulting in the selection of three lower lobe patients. This
enabled us to focus on images for which the highest dosi-
metric efficiency of abdominal compression was expected.
An upper lobe patient with artifact-free images was also
chosen to extend the study to another location in the lung.
Thus four of the 27 patients initially included were selected
(see Figs. 3 and 4 for more details).
The dosimetric study consisted of assessing the impact
of abdominal compression in terms of dose received by the
healthy lung tissue. Treatment planning was performed on
untagged images. The ITV was delineated (FOCAL, CMS)Figure 3 Modification of the overall tumor motion amplitude in m
tumor motion amplitudes due to the use of abdominal compres
dosimetric study. Also presented are the p values concerning t
abdominal compression.on the 4DCT MIP reconstruction and the lungs were delin-
eated on the untagged images. The planning target volume
(PTV) resulted from the addition of a 8 mm margin around
the ITV in the cranio-caudal direction and 5 mm in the left-
right and antero-posterior directions. The treatment plan
consisted of 12 static coplanar fields of 6 MV photon beams.
The fields were shaped to the PTV without additional
margins, equally-distributed around the patient and
equally-weighted. A dose of 48 Gy (4 fractions) was
prescribed to the 80% isodose line. We made sure that at
least 95% of the PTV was conformally covered by the
prescription isodose line [9] and the coverage was similar in
the two CT scans (with and without abdominal compres-
sion). Dose calculation was performed on a XiO worksta-
tion (CMS) using a superposition algorithm and a 2 mm
calculation grid. Then we analyzed the lung dose-volume
histograms (DVH). We examined the influence of abdominal
compression on the lung volume receiving 16 Gy (V16) and
20 Gy (V20), on the dose received by 1000 cm
3 (D1000) and
1500 cm3 (D1500) of lung and on the mean lung dose (Dmean),
since all these parameters have been reported to be
predictive of lung toxicity [9].
Results
Geometrical efficiency
Free (i.e. without abdominal compression) tumor motion
amplitude was 12.4 mm in average (SD 6.5 mm, range
2.6e24.7 mm) for tumors in the lower lobe and 4.9 mm (SD
3.8 mm, range 1.2e14.1 mm) for the upper/middle lobe.
When applying the compression, mean tumor motion
amplitude was reduced to 8.9 mm (SD 4.2 mm, range
1.7e16.4 mm) for lower lobe tumors and 4.1 mm (SD
3.4 mm, range 0.0e13.1 mm). Figure 3 shows modifications
of tumor motion amplitude using abdominal compression.
Results are sorted by cranio-caudal position, distinguishing
between lower and upper/middle lobe locations. Overall,m. Negative (positive) values represent decreased (increased)
sion. Boxed results correspond to patients selected for the
he difference between the data obtained with and without
Figure 4 Modification of the internal target volume in cm3 depending on tumor location. Negative (positive) values represent
decreased (increased) internal target volumes due to the use of abdominal compression. Boxed results correspond to patients
selected for the dosimetric study. Also presented are the p values concerning the difference between the data obtained with and
without abdominal compression.
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(p Z 0.002) in the 28 tumors involved in the study, with
a mean reduction of 1.7 mm. However, the results showed
a variable influence of abdominal compression. A substan-
tial reduction (>3 mm) was observed for 6 of the 28 tumors,
a null or minor reduction (<3 mm) was obtained in 17
tumors, whereas for the 5 remaining patients the
compression slightly increased tumor motion amplitude
(maximum observed increase of 2.3 mm).
The most significant benefit of abdominal compression
was obtained in lower lobe tumors (pZ 0.009) with a mean
amplitude reduction of 3.5 mm (SD 3.6 mm, range
1.2e8.3 mm). The compression had a significant but limited
influence for upper/middle lobe locations (pZ 0.026) with
a mean reduction of 0.8 mm (SD 1.6 mm, range
2.3e4.0 mm). Negative effects resulting in a motion
amplitude increase could be observed independently of
tumor location.
Mean tumor size, corresponding to the largest tumor
dimension, was 2.4 cm (SD 1.5 cm, range 1e5 cm) for the
lower lobe and 2.1 cm (SD 0.9 cm, range 1e4 cm) for the
upper/middle lobe. Figure 4 presents the influence of
abdominal compression on the ITV analyzed using the
theoretical approach described in Geometrical study. A
notable reduction (>2 cm3) of the ITV was observed for 4
patients, all with lower lobe tumors. A mean reduction of
3.6 cm3 (SD 5.4 cm3, range 0.1e16.3 cm3) was obtained
for lower lobe lesions (p Z 0.039) and of 0.2 cm3 (SD
0.6 cm3, range 1.1e1.6 cm3) for upper/middle lobe
lesions (p Z 0.048). The overall mean ITV reduction was
1.3 cm3 in the 28 lesions and the influence of abdominal
compression on the ITV was less significant (pZ 0.024) than
variations in tumor motion amplitude.
Dosimetric benefit
Absolute dosimetric gains are presented in Table 1. The
mean relative modifications of dosimetric parameters were7%, 5%, 5%, 14% and 0% for V16, V20, D1000, D1500 and
Dmean, respectively. The maximum relative gains were
observed for lower lobe patients with modifications of
16% (patient 1), 19% (patient 1), 19% (patient 2), 33%
(patient 3) and 15% (patient 3) for V16, V20, D1000, D1500
and Dmean, respectively. A degradation of dosimetric
parameters could also be observed with the use of
abdominal compression for patient 3 with modifications of
þ8%, þ25% and þ15% for V20, D1000 and Dmean, respectively.
Discussion
Abdominal compression systematically reduces motion
amplitude for tumors close to the diaphragm but it can
have very different effects in other locations. Globally, the
benefit on middle and upper lobe tumor motion is very
limited whereas the gain can be important but is not
systematic in lower lobe locations. An increase of motion
amplitude could even be observed for 18% of the tumors,
independently of the location. It may be due to the fact
that, under abdominal compression, patients tend to
breathe with the upper thoracic region, the lower part
being immobilized. In addition, abdominal compression can
increase the variability of tumor motion because of patient
discomfort and anxiety [18].
Table 2 summarizes results reported by previous studies
[19e22]. We obtained a significant mean reduction of
3.5 mm for lower lobe tumors (p Z 0.009). Heinzerling
et al. [20] have reported higher results with a significant
mean motion reduction of 5.3 and 6.4 mm (p < 0.0001) with
two compression levels. The difference can be attributed
to the fact that motion of both liver and lower lung lobe
tumors was analyzed in this study. This suggests that
abdominal compression is more efficient in reducing tumor
motion in the liver than in the lower lung lobes. It is in
accordance with Wunderink et al. [30] who have reported
high efficiency of abdominal compression in reducing liver
tumor motion. Concerning overall tumor motion amplitude
Table 1 Absolute modifications of lung dosimetric parameters due to the use of abdominal compression according to tumor
location: lower lobe (LL) and upper/middle lobe (UML).
Patient (location) 1 (LL) 2 (LL) 3 (LL) 4 (UML) Mean
Volumetric
parameters
PTV (cc) 13.01 9.46 1.82 6.19 7.62
Lungs (Left þ Right e PTV) (cc) 131.01 164.57 107.07a 153.89 139.13
Dosimetric
parameters
Lungs (Left þ Right e PTV) V16 (%) 0.82 0.87 0.06 0.24 0.50
V20 (%) 0.63 0.42 þ 0.17 0.24 0.28
D1000 (Gy) 0.65 1.80 þ 0.42 0.16 0.55
D1500 (Gy) 0.11 0.57 0.2 0.05 0.23
Dmean (Gy) 0.29 0.33 þ 0.54 0.05 0.03
a Data available for the left lung only because this patient had a pulmonectomy.
338 G. Bouilhol et al.in the whole lung, our results (1.7 mm mean reduction,
pZ 0.002) compared favorably with those of Han et al. [21]
(1.3 mm, p < 0.05). The comparison of our results with
those of Negoro et al. [19] was performed by restricting our
analysis to cranio-caudal tumor displacements and to
tumors with motion amplitude greater than 5 mm (10
patients). We found that abdominal compression signifi-
cantly reduces tumor motion (p Z 0.005) from a range of
6e24 mm (mean 13.0 mm) to a range of 6e16 mm (mean
9.6 mm). These results are in agreement with those of
Negoro et al. [19] who have reported a significant reduction
(p Z 0.0002) from a range of 8e20 mm (mean 12.3 mm) to
a range of 2e11 mm (mean 7.0 mm). Focusing on cranio-
caudal direction to compare with Bengua et al. [22], we
obtained a significant mean amplitude reduction of 3.6 mm
for lower lobe tumors (p Z 0.006) and 0.2 mm for upper/
middle lobe tumors (p Z 0.007). These results are
substantially different from those of Bengua et al. [22] who
have obtained no significant motion reduction with a mean
of 0.48 mm for middle or lower lobe markers (pZ 0.65) and
0.46 mm for upper lobe markers (pZ 0.61). This difference
may stem from the fact that the patients involved in their
study were able to monitor their breathing amplitude from
a respiration range indicator. Moreover, the gold markers
used for tumor tracking were not systematically placedTable 2 Previous studies on efficiency of abdominal compressi
Authors Year N Location Modality
Negoro
et al. [19]
2001 10 e Fluorosc
Heinzerling
et al. [20]
2008 10 LL(4) þ liver(6) 4DCT
Han
et al. [21]
2010 24 UL(16), ML(2), LL(7) 4DCT
Bengua
et al. [22]
2010 19 UL(11), ML(1), LL(7) RTRT sys
Abbreviations: UL, upper lobe; ML, middle lobe; LL, lower lobe; RTRT
CC, cranio-caudal.
a Results are given according to lobe tumor location.inside the tumor. However, one must keep in mind that the
differences observed between the present study and liter-
ature may also be attributed to the use of different
compression levels [20].
Results are more manifest regarding the influence of
compression on the ITV. Indeed, an important benefit in
tumor motion amplitude is necessary but not sufficient to
obtain a notable volumetric gain. The reduction in motion
must apply to large enough tumors to be really beneficial,
but large tumors are not frequent in SBRT patients. To
overcome problems in the measurement of the ITV in
presence of motion artifacts in the tumor region, the
modification of the ITV has been assessed using the land-
mark annotations on the tumor extreme phases and
making the assumption of a one-dimensional displacement
between them. This assumption does not account for
potential tumor motion hysteresis [31,32] but the aim was
just to emphasize the fact that the reduction of the ITV is
limited by the small size of the tumors treated with SBRT.
In spite of observable gains in ITV and PTV, the benefit of
abdominal compression on lung dosimetric parameters
appeared to be limited. The reason is that the compression
not only reduces the target volume, but also has the
systematic effect of reducing the lung volume (as observed
by Kontrisova et al. [23]). Therefore, the proportion of theon associated with the SBF for reducing lung tumor motion.
Direction Results
opy CC Reduction from a range
of 8e20 mm (mean 12.3 mm)
to a range of 2e11 mm
(mean 7.0 mm) (p Z 0.0002)
LR, AP, CC þ 3D Mean 3D reduction of 5.3 and
6.4 mm with two compression
levels (p < 0.0001)
LR, AP, CC þ 3D Mean 3D reduction of 1.3 mm
(p < 0.05)
tem LR, AP, CC In CC direction: mean reduction
of 0.48 mm for middle or lower
lobe markers (p Z 0.65) and
0.46 mm for upper lobe
markers (p Z 0.61)a
, real-time radiation therapy; LR, left-right; AP, antero-posterior;
Usefulness of abdominal compression in lung SBRT 339lung receiving a given dose and the dose received by a given
volume remained stable. The relative variations that can
seem important at first are actually far from absolute
variations that would compromise the respect of the lung
critical doses. Indeed, SBRT treatments concern small
tumors and thus small field sizes. According to RTOG
protocols [8,9], three-dimensional custom designed
coplanar or non-coplanar fields must be used to deliver
highly conformal radiation doses but non-opposing and non-
coplanar beams are preferable. Moreover, roughly equally-
weighted beams are typically used. In order to be able to
compare the two modalities (with and without compres-
sion) for all the patients, we systematically used equally-
distributed and equally-weighted fields. This way, only
the impact of volume modifications induced by the use of
abdominal compression is assessed, without being influ-
enced by potential patient-dependent discrepancies in
beam arrangements. In most cases, the respect of the lung
critical doses can be achieved by adjusting field weights
and/or distribution. Our dosimetric results reflect smaller
reduction when using abdominal compression than the
results presented by Kontrisova et al. [23]. This may be
caused by the use of different images to delineate the GTV
(3DCT blurred vs. 4DCT MIP), by the use of different CTV to
PTV margins, or by the fact that results reported by Kon-
trisova et al. [23] concern the ipsilateral lung and not theFigure 5 Reduction of motion artifacts with the use of
abdominal compression. Slices acquired with (top) and without
(bottom) compression.whole healthy lung tissue (left lung þ right lung e PTV). A
subsample of 4 patients does not allow drawing general
conclusions about the efficiency of abdominal compression
in reducing healthy lung tissue exposure. However, the
chosen patients revealed the highest geometrical gains,
illustrating the highest expected dosimetric benefits of the
use of compression.
Another consequence of the use of abdominal
compression concerns motion artifacts in 4DCT images.
Irregularities in the respiratory signal lead to motion arti-
facts in the reconstructed images. Motion artifacts in 4DCT
images reflect interplay between organ motion and scan-
ning movements (gantry rotation and couch displacement).
Yamamoto et al. [29] have found that 90% of the patients
have at least one motion artifact in 4DCT images. The end-
exhale phase is generally the least prone to artifacts
because motion is slow and it is reproducible, making it the
most stable phase of the breathing cycle [33]. The
compression modifies global patient respiration character-
istics such as amplitude, frequency or regularity. Conse-
quently, for given acquisition parameters, abdominal
compression can limit the occurrence of motion artifacts
(Fig. 5) or introduce some. For the patients taking part in
this study, we mainly observed an artifact reduction (for 16
patients) whereas artifact increase was less frequent (5
patients).
Conclusions
The use of abdominal compression for lung SBRT treatments
efficiently reduces motion amplitude for lesions close to
the diaphragm. If the tumors are large enough, abdominal
compression can be associated with an interesting reduc-
tion of the internal target volume. For other locations, the
use of the compression can provide a minor benefit or even
induce unwanted effects such as tumor motion and ITV
increase. We have shown that only a small gain in lung
healthy tissue sparing could be achieved with the use of
abdominal compression.
Based on these findings and taking into account that
such a system is time-consuming and not always well-
tolerated, we have decided to stop using abdominal
compression when treating patients with upper and middle
lobe tumors. On the contrary, patients with lower lobe
lesions still undergo two 4DCT exams, with and without
abdominal compression. The relevance of using the
compression is evaluated on an individual basis and the
decision is taken according to patient tolerance and the
expected benefit.
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